FMP

FMP

Enter

MRKR - Marker Therapeutics,...

photo-url-https://images.financialmodelingprep.com/symbol/MRKR.png

Marker Therapeutics, Inc.

MRKR

NASDAQ

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

2.24 USD

-0.225 (-10.07%)

About

ceo

Dr. Juan F. Vera M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

CIK

0001094038

ISIN

US57055L2060

CUSIP

57055L107

Address

3200 Southwest Freeway

Phone

713 400 6400

Country

US

Employee

8

IPO Date

Jul 16, 2002

Key Executives

Name

Title

Pay

Year Born

Ms. Mary Newman Ph.D.

Head of Regulatory Affairs

0

1959

Ms. Elizabeth Donnelly

Director of Administration

0

N/A

Dr. Maria-Bernadette Madel

Director of Corporate Operations & Exter...

0

1990

Dr. Robert Z. Florkiewicz Sr.

Senior Director of Molecular Biology & V...

0

N/A

Dr. Monic Stuart M.D.

Chief Medical Officer

0

N/A

Patricia Allison

Head of Clinical Operations

0

N/A

Dr. Juan F. Vera M.D.

Co-Founder, Chief Executive Officer, Pre...

399.25k

1980

Mr. Edmund Cheung

Vice President of Human Resources

0

N/A

As of December 31, 2024, the total employee count stands at 8, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep